戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ally corrected HSC threshold that corrects a hematopoietic disease.
2 portant field of therapeutic development for hematopoietic disease.
3 opoietic stem cell (HSC) source for treating hematopoietic disease.
4 therapeutic approach for FLT3-ITD-associated hematopoietic disease.
5 sensitive and automated diagnosis of complex hematopoietic diseases.
6 ch has been extensively studied in malignant hematopoietic diseases.
7 rtant function in blood cell homeostasis and hematopoietic diseases.
8 ility is a target for the treatment of these hematopoietic diseases.
9  vectors will be effective in treating human hematopoietic diseases.
10 ed into cell types that can be used to treat hematopoietic diseases.
11 major obstacle to successful gene therapy of hematopoietic diseases.
12 vivo evaluation of therapies targeting human hematopoietic diseases.
13 HSC) transplantation, the only cure for most hematopoietic diseases.
14 and for studying abnormal gene expression in hematopoietic diseases.
15 rs have been an obstacle to gene therapy for hematopoietic diseases.
16  been a major impediment to gene therapy for hematopoietic diseases.
17 rray of hematopoietic malignancies and other hematopoietic diseases.
18  or improvement of the course of age-related hematopoietic diseases.
19 iPSCs) hold great promise for modeling human hematopoietic diseases.
20 nd defects have been implicated in malignant hematopoietic diseases.
21 stinctions between RP gene mutations driving hematopoietic disease and those resulting in development
22 aftment, thereby providing a model for human hematopoietic diseases and treatments not previously ava
23 re enriched in many major disease types like hematopoietic diseases, cardiovascular diseases, cancers
24          Chronic myeloid leukemia (CML) is a hematopoietic disease characterized by expansion of myel
25                             Gene therapy for hematopoietic diseases has been hampered by the low freq
26 or studying the role of RAS dysregulation in hematopoietic disease in general and in discrete human d
27 sis of spontaneous cancers or modeling human hematopoietic diseases in mice.
28 th MGMTP140K has broad potential for several hematopoietic diseases including hemoglobinopathies.
29 les in JAK2 activation in the development of hematopoietic diseases including myeloproliferative neop
30 morphic RUNX2 alleles can cause CCD, whereas hematopoietic disease requires more severely inactivatin
31 iral-mediated gene transfer for nonmalignant hematopoietic diseases such as LAD.
32 rapy can potentially cure a variety of human hematopoietic diseases, such as sickle cell disease.
33      Wiskott-Aldrich syndrome is an X-linked hematopoietic disease that manifests itself in platelet
34 hildren with Down syndrome exhibit 2 related hematopoietic diseases: transient myeloproliferative dis
35  potential targets for treatment of numerous hematopoietic diseases using retroviral-mediated gene tr
36                      Retroviruses can induce hematopoietic disease via insertional mutagenesis of can
37 to study the effects of RAS dysregulation in hematopoietic disease, we developed separate founder lin
38 5 in the abnormal activation of JAK2-induced hematopoietic diseases, we generated a stable transfecta
39   The success of retrovirus gene therapy for hematopoietic diseases will be limited both by the effic